R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, NAS of Ukraine, Kyiv 03022, Ukraine.
Kyiv City Clinical Oncological Center, Kyiv 03115, Ukraine.
Exp Oncol. 2020 Sep;42(3):162-166. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-3.14805.
To identify the association of serum miRNAs with neoadjuvant polychemotherapy response in patients with breast cancer of luminal A and B subtypes.
We analyzed the expression levels of circulating miR-21, -155, -182, -373, -199a, -205, -375 in serum of 182 breast cancer patients using real-time polymerase chain reaction. Each case was characterized by TMN criteria using morphological and immunohistochemical analyses.
Serum levels of miR-205 and -375 are associated with the response of luminal A tumors and miR-205 and -21 with the response of luminal B tumors to neoadjuvant polychemotherapy in fluorouracil + doxorubicin + cyclophosphamide and doxorubicin + cyclophosphamide regimens. In addition, we found correlation of miR-155, -182, -199a, -375 with 3-year relapse-free survival of patients. Based on the obtained data, we developed innovative prognostic and predictive panels to assess the drug sensitivity of tumors and lower the risk of breast cancer recurrence, which would significantly improve the treatment outcomes and the quality of life of patients.
Serum levels of miR-155, -182, -199a, -205, -375 can be used as predictive and prognostic panel for monitoring BC course in Ukrainian population.
鉴定血清 microRNAs 与 luminal A 和 B 型乳腺癌患者新辅助化疗反应的相关性。
我们采用实时聚合酶链反应分析了 182 例乳腺癌患者血清中循环 miR-21、-155、-182、-373、-199a、-205、-375 的表达水平。每个病例均采用形态学和免疫组织化学分析的 TMN 标准进行特征描述。
血清 miR-205 和 -375 水平与 luminal A 肿瘤的反应相关，miR-205 和 -21 与氟尿嘧啶+多柔比星+环磷酰胺和多柔比星+环磷酰胺方案中 luminal B 肿瘤对新辅助化疗的反应相关。此外，我们发现 miR-155、-182、-199a、-375 与患者 3 年无复发生存率相关。基于获得的数据，我们开发了创新的预后和预测面板，以评估肿瘤的药物敏感性并降低乳腺癌复发的风险，这将显著改善患者的治疗效果和生活质量。
血清 miR-155、-182、-199a、-205、-375 水平可作为监测乌克兰人群乳腺癌病程的预测和预后面板。
